Vittoria Biotherapeutics, INC
Philadelphia, PA
United States
TAP Partner
Vittoria Biotherapeutics is developing novel CAR-T cell therapies that transcend the limitations of current cell therapies. Based on technology exclusively licensed from the University of Pennsylvania, Vittoria's proprietary Senza5 platform unlocks the antitumor potential of engineered T cells and utilizes a five-day manufacturing process to maximize stemness, durability, and target cell cytotoxicity. By acting on the fundamental biology of T cells, Senza5 can be used to improve the efficacy of engineered T cell therapies with pipeline applications in oncology and autoimmune diseases.
Program Name(s)
Therapy Acceleration Program
![Vittoria](/sites/default/files/styles/inspirational_stories_square/public/2023-10/Vittoria_web_SQ.png?itok=CvjS9qUW)